Incretin-based peptides have become some of the most widely studied compounds in metabolic research. They work by mimicking hormones the gut naturally releases after a meal, signaling the pancreas and brain in ways that affect blood sugar and appetite. Most people who participate in clinical trials with these agents tolerate them well, but a small number develop allergic reactions. Understanding exactly what triggered a reaction, and whether a related peptide might be safe, is a genuine clinical puzzle.
A case report published in Clinical Case Reports describes precisely that puzzle. A 25-year-old woman tolerated several months of escalating doses of tirzepatide, a dual-receptor peptide that targets both the GLP-1 and GIP pathways, then developed a prolonged skin reaction after a higher dose. The reaction did not resolve with standard antihistamine and steroid treatments. Eventually, structured allergy testing pointed to a drug-specific immune response and revealed that a closely related peptide, semaglutide, appeared safe for her to use.
The case is notable less for the reaction itself, which is rare, and more for the diagnostic approach the clinicians used. Intradermal testing and a supervised drug challenge gave a concrete answer where guesswork alone could not.
Background on the peptides involved
Tirzepatide is a synthetic peptide designed to activate two receptors at once: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Researchers have studied this dual mechanism because activating both receptors together appears to produce larger effects on blood sugar regulation and body weight than activating either receptor alone.
Semaglutide is a different synthetic peptide that targets only the GLP-1 receptor. It shares the same general receptor family as tirzepatide but has a distinct molecular structure. The two compounds belong to the same broad drug class, yet they are not identical in the way their amino acid sequences are arranged or in how they interact with the immune system.
Both compounds are delivered by subcutaneous injection in the doses studied for metabolic conditions. Both have been the subject of large clinical trials. Their structural differences, however, mean that an immune response to one does not automatically predict a response to the other.
What happened in the reported case
The patient in the case report was a 25-year-old woman with a body mass index placing her in the class I obesity range. She began tirzepatide at 2.5 mg and increased her dose over roughly three months, reaching 7.5 mg without any notable reaction. During that period she lost approximately 20 pounds, which the report notes in describing her clinical history.
After her first injection at the 10 mg dose, she developed episodic swelling of the lips, a condition called angioedema, along with generalized hives across her body. These symptoms appeared over the following four days. Crucially, she had no respiratory or gastrointestinal involvement, which would have raised the concern for a more severe systemic reaction.
Treatment attempts included an intramuscular antihistamine injection, a five-day course of oral corticosteroids, and two separate emergency department visits where she received intravenous steroids. None of these interventions resolved the symptoms. Her condition only improved after tirzepatide was discontinued entirely.
The report also notes that laboratory work done roughly eight months before this episode, following a separate unrelated incident of lip swelling, had already ruled out hereditary and acquired angioedema by showing normal levels of C1 esterase inhibitor and complement proteins. That earlier workup helped narrow the picture considerably.
Allergy testing and what it showed
Once tirzepatide was discontinued and symptoms resolved, the clinical team pursued formal allergy evaluation. Standard percutaneous skin testing, in which a diluted solution of the drug is pricked onto the skin surface, came back negative for tirzepatide. A negative result at this stage does not rule out hypersensitivity; it simply means the reaction threshold was not met at the skin surface.
Intradermal testing, which involves injecting a small amount of diluted drug directly into the skin layer, produced a different result. At a 1:10 dilution, the tirzepatide test produced a wheal of 8 mm and a flare of 8 mm, a positive result by standard allergy criteria. This confirmed that the patient's immune system was mounting a response specific to tirzepatide.
The same intradermal testing performed with semaglutide returned a negative result. Based on this finding, the clinical team proceeded to a supervised subcutaneous challenge. The patient received a 0.25 mg dose of semaglutide under direct medical observation and tolerated it without any adverse reaction. She was subsequently cleared to begin semaglutide under endocrinology supervision, and the report states she has continued using it without recurrence of symptoms.
Why this pattern is scientifically interesting
From a research standpoint, the case illustrates that hypersensitivity within a drug class does not automatically extend to every member of that class. Tirzepatide and semaglutide both interact with the GLP-1 receptor, but their molecular structures differ enough that the immune system appears to distinguish between them. The patient's immune response was directed at something specific to tirzepatide, whether that is its unique amino acid sequence, its dual-receptor binding domain, or some other structural feature the authors do not pinpoint.
The literature on hypersensitivity to GLP-1 receptor agonists as a group is still limited. The authors describe such reactions as uncommon but clinically significant. Reports specifically involving tirzepatide are even more scarce, which makes this case a useful data point for researchers and clinicians trying to understand the safety profile of the newer dual-receptor peptides.
Early data from this and similar cases points at the value of going beyond percutaneous testing when drug hypersensitivity is suspected. The surface-level skin test missed the reaction that intradermal testing caught. Without the intradermal step, the clinical team might not have confirmed the diagnosis with the same confidence.
The role of supervised challenge protocols
A supervised drug challenge is a structured procedure in which a patient receives a low starting dose of a compound under direct medical observation, with equipment and personnel on hand in case a reaction occurs. The protocol used here served two purposes: it confirmed that semaglutide was tolerated, and it provided a controlled environment where any reaction could have been managed immediately.
The case report frames this combination of intradermal testing followed by supervised challenge as a model for approaching suspected drug-specific hypersensitivity within a peptide class. Rather than simply avoiding all related compounds after a single reaction, this approach allows clinicians to test alternatives systematically. The authors describe the diagnostic utility as the central lesson of the case.
Limitations and what remains open
A single case report carries inherent limitations. It describes one patient with one outcome and cannot establish how frequently this pattern occurs across the broader population of people who use these peptides. The mechanism behind the tirzepatide-specific reaction is not established. The authors do not identify whether the immune response was IgE-mediated or driven by another pathway, partly because standard IgE testing was not specific enough to answer that question.
Researchers studying hypersensitivity to synthetic peptides in this class will need larger retrospective datasets or prospective registries to understand incidence rates, risk factors, and the structural features most likely to trigger immune responses. This case adds one well-documented observation to what remains a small body of literature.
